Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Timbetasin - Lee's Pharmaceutical

Next Previous
Drug Profile

Timbetasin - Lee's Pharmaceutical

Alternative Names: Germinal peptide eye drops; LQ 7; Shengfatai eye drops; ZKY-001

Latest Information Update: 02 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lee's Pharmaceutical
  • Developer Zhaoke Pharmaceutical (Hefei)
  • Class Anti-infectives; Anti-inflammatories; Anti-ischaemics; Antibronchitics; Antidementias; Antifibrotics; Eye disorder therapies; Foot disorder therapies; Heart failure therapies; Neuroprotectants; Peptide hormones; Peptides; Proteins; Skin disorder therapies; Thymus hormones; Vascular disorder therapies
  • Mechanism of Action Actin modulators; Amyloid inhibitors; Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants; Heat-shock protein modulators; MicroRNA modulators; Nerve growth factor stimulants; NF-kappa B inhibitors; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Corneal disorders

Most Recent Events

  • 24 Jan 2023 Phase-II development is ongoing in China (NCT04228926)
  • 24 Jan 2023 Zhaoke Pharmaceutical plans to submit an NDA to the NMPA in 2024 (Zhaoke Pharmaceutical pipeline, January 2023)
  • 31 Dec 2022 Zhaoke Pharmaceutical plans a phase III trial in the second half of 2022 (Zhaoke Pharmaceutical pipeline, January 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top